XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Subsequent Events (Details)
9 Months Ended
Nov. 08, 2022
USD ($)
shares
Nov. 07, 2022
Oct. 27, 2022
Oct. 26, 2022
shares
Oct. 03, 2022
USD ($)
$ / shares
shares
Aug. 04, 2022
$ / shares
shares
Aug. 03, 2022
shares
Sep. 30, 2022
USD ($)
Vote
$ / shares
shares
Sep. 30, 2021
USD ($)
Nov. 09, 2022
shares
Subsequent Event [Line Items]                    
Issuance of common stock and warrants, net of issuance costs (in shares)           931,667 36,196      
Warrants exercise price (in dollars per share) | $ / shares           $ 6.00        
Term of warrants           5 years        
Issuance costs | $               $ 1,061,520 $ 1,061,520  
Percentage of cashless warrants exercised             20.00%      
Number of common shares to issue on exercise of warrants               144,866    
TardiMed                    
Subsequent Event [Line Items]                    
Number of common shares to issue on exercise of warrants             36,196 181,083    
October 2022 Offerings                    
Subsequent Event [Line Items]                    
Proceeds from the issuance of common stock and warrants, gross | $               $ 1,000,000.0    
Series 2 Warrants | October 2022 Offerings                    
Subsequent Event [Line Items]                    
Warrants exercise price (in dollars per share) | $ / shares               $ 6.00    
Series B preferred stock                    
Subsequent Event [Line Items]                    
Number of shares cancelled 13,000                  
Consideration from stock cancellation | $ $ 0                  
Series B preferred stock | October 2022 Offerings                    
Subsequent Event [Line Items]                    
Preferred stock, par value | $ / shares               0.001    
Average minimum bid price per share | $ / shares               $ 0.20    
Votes per share | Vote               10,000,000    
Subsequent event                    
Subsequent Event [Line Items]                    
Reverse stock split 0.02   0.02              
Subsequent event | Minimum                    
Subsequent Event [Line Items]                    
Reverse stock split   0.04                
Subsequent event | Maximum                    
Subsequent Event [Line Items]                    
Reverse stock split   0.02                
Subsequent event | TardiMed                    
Subsequent Event [Line Items]                    
Issuance of common stock and warrants, net of issuance costs (in shares)       36,166            
Percentage of cashless warrants exercised       20.00%            
Number of common shares to issue on exercise of warrants                   108,700
Subsequent event | October 2022 Offerings | Wainwright                    
Subsequent Event [Line Items]                    
Percentage of stock issuance cost         6.00%          
Issuance costs | $         $ 40,000          
Non accountable expenses | $         25,000          
Clearing expenses | $         $ 15,950          
Subsequent event | Series B preferred stock                    
Subsequent Event [Line Items]                    
Number of shares cancelled 13,000                  
Consideration from stock cancellation | $ $ 0                  
Subsequent event | Securities Purchase Agreement | October 2022 Offerings                    
Subsequent Event [Line Items]                    
Issuance of common stock and warrants, net of issuance costs (in shares)         260,000          
Warrants exercise price (in dollars per share) | $ / shares         $ 5.00          
Proceeds from the issuance of common stock and warrants, gross | $         $ 1,300,000          
Subsequent event | Securities Purchase Agreement | Series 1 Warrants | October 2022 Offerings                    
Subsequent Event [Line Items]                    
Number of common shares to issue on exercise of warrants         260,000          
Subsequent event | Securities Purchase Agreement | Series B preferred stock | October 2022 Offerings                    
Subsequent Event [Line Items]                    
Number of common shares to issue on exercise of warrants         13,000